afatinib + ritonavir

**Afatinib + ritonavir** is a combination of two pharmaceutical drugs: afatinib, an irreversible oral ErbB family (EGFR, HER2, HER4) tyrosine kinase inhibitor primarily indicated for non-small cell lung cancer, and ritonavir, a protease inhibitor used predominantly as a pharmacokinetic enhancer due to its potent inhibition of CYP3A and P-glycoprotein (P-gp). Ritonavir increases systemic exposure to drugs that are substrates of these pathways, especially by inhibiting P-gp activity, which reduces drug efflux and increases absorption of co-administered agents like afatinib. This combination does not have a unique brand or code name and is not established as a marketed or investigational product, but both drugs are occasionally coadministered with attention to pharmacokinetic interactions. The combination may mildly increase afatinib exposure, depending on the timing of administration, but this can be managed by separating doses or adjusting afatinib dosage, and clinical interaction is not viewed as highly significant if managed appropriately[1][2][3][4][5].

Brand names

NorvirGilotrif